Actively Recruiting
Magnetic Resonance Spectroscopy Biomarkers in Type 3 Gaucher Disease (GD3)
Led by University of Minnesota ยท Updated on 2026-01-08
5
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on adult patients with Type 3 Gaucher Disease (GD3), a condition with neurological involvement. Researchers are studying how brain chemicals, called neurometabolites, change in these patients using magnetic resonance spectroscopy (MRS). The goal is to find new biomarkers that can help show how patients respond to treatment and to understand how these brain chemicals relate to disease features like genotype, enzyme levels, and other Gaucher disease markers. The study is observational and does not involve any intervention or treatment. Participants will undergo MRS to measure brain chemicals linked to oxidative stress and inflammation. This approach aims to characterize the neurometabolite profiles in patients who are medically stable and on stable therapy for GD3. Participants must be adults aged 18 to 80 who are medically stable and able to cooperate with study procedures. Throughout the study, researchers will collect MRS data at baseline to assess neurometabolite profiles. Participants will also be evaluated for safety and ability to complete the study protocol. The research is conducted by the University of Minnesota and will continue through July 2026.
CONDITIONS
Brief Title
MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 years or older.
- Must be able to understand and cooperate with study requirements and provide written informed consent.
- Diagnosed with Type 3 Gaucher Disease and medically stable for participation as determined by the investigator.
You will not qualify if you...
- Medically unstable conditions as determined by the investigators.
- Any concurrent disease or medical condition that may affect safety, study compliance, or data integrity.
- Women who are pregnant, lactating, or of child-bearing age not using acceptable contraception.
- Participation in another interventional study.
- Inability or unwillingness to have blood drawn.
- Unable to undergo MRI scanning due to claustrophobia, presence of metal implants, weight over 300 lbs, or inability to remain still for 30 minutes.
- Unable to adhere to the study protocol for any reason.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single timepoint
Participants undergo magnetic resonance spectroscopy (MRS) to assess brain chemicals related to oxidative stress and inflammation.
1 visit (in-person)
Duration - Up to study completion
Participants are observed over time to monitor neurometabolite profiles and clinical status without receiving any intervention.
Follow-up visits as scheduled by the study team
Trial Site Locations
Total: 1 location
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
R
Reena Kartha, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here